DE3855236D1 - Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen - Google Patents

Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen

Info

Publication number
DE3855236D1
DE3855236D1 DE3855236T DE3855236T DE3855236D1 DE 3855236 D1 DE3855236 D1 DE 3855236D1 DE 3855236 T DE3855236 T DE 3855236T DE 3855236 T DE3855236 T DE 3855236T DE 3855236 D1 DE3855236 D1 DE 3855236D1
Authority
DE
Germany
Prior art keywords
people
autoimmune diseases
treating vital
treating
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3855236T
Other languages
English (en)
Inventor
Thomas Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Commerce
Original Assignee
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Commerce filed Critical US Department of Commerce
Application granted granted Critical
Publication of DE3855236D1 publication Critical patent/DE3855236D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE3855236T 1987-08-17 1988-08-11 Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen Expired - Lifetime DE3855236D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8570787A 1987-08-17 1987-08-17
PCT/US1988/002731 WO1989001340A1 (en) 1987-08-17 1988-08-11 Method for treating malignancy and autoimmune disorders in humans

Publications (1)

Publication Number Publication Date
DE3855236D1 true DE3855236D1 (de) 1996-05-30

Family

ID=22193428

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3855236T Expired - Lifetime DE3855236D1 (de) 1987-08-17 1988-08-11 Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen

Country Status (7)

Country Link
US (1) US20050207975A1 (de)
EP (1) EP0380542B1 (de)
JP (1) JP2581788B2 (de)
AT (1) ATE137119T1 (de)
CA (1) CA1325591C (de)
DE (1) DE3855236D1 (de)
WO (1) WO1989001340A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
JPH03503887A (ja) * 1988-02-03 1991-08-29 エクソウマ　コーポレーション 自己免疫疾患に対する抗ｔ細胞イムノトキシンの治療的使用
US5276348A (en) * 1992-06-09 1994-01-04 Advanced Photonix, Inc. Dot matrix pattern on photosensitive semi-conductor surface
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
FI95441C (fi) * 1994-05-31 1996-02-12 Leiras Oy Inhalointilaitteen lääkeainekammio
KR100465820B1 (ko) * 2002-04-16 2005-01-13 심대근 문짝용 플라스틱 판넬 및 그 제조 방법
ES2401136T3 (es) 2002-11-15 2013-04-17 Genmab A/S Anticuerpos monoclonales humanos contra CD25

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US903723A (en) * 1907-12-23 1908-11-10 Nelson Hughes Buckle.
SU438419A1 (ru) * 1968-05-31 1974-08-05 Н. Б. Михеев, М. А. Грачева , А. И. Журба Институт биофизики Способ получения коллоидного растворас иттрием-90
DE2011612C3 (de) * 1970-03-11 1974-03-21 Institut Medizinskoi Radiologii Amn Ssr, Ussr, Obninsk (Sowjetunion) Radionuklide enthaltende, resorbierbare Fäden und Filme
US4709015A (en) * 1979-12-04 1987-11-24 Ortho Pharmaceutical Corporation Monoclonal antibody to human suppressor T cells
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4819150A (en) * 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
FR2616330B1 (fr) * 1987-06-12 1990-12-21 Immunotech Sa Agent actif et medicament en contenant destines a prevenir ou a combattre le rejet de greffe d'organe chez l'homme
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins

Also Published As

Publication number Publication date
ATE137119T1 (de) 1996-05-15
WO1989001340A1 (en) 1989-02-23
US20050207975A1 (en) 2005-09-22
EP0380542B1 (de) 1996-04-24
JPH03500645A (ja) 1991-02-14
JP2581788B2 (ja) 1997-02-12
CA1325591C (en) 1993-12-28
EP0380542A1 (de) 1990-08-08
EP0380542A4 (en) 1990-12-05

Similar Documents

Publication Publication Date Title
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
HUS1600042I1 (hu) Anti-CS1 antitestek terápiás alkalmazása
HRP950052B1 (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
DE3855236D1 (de) Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen
ES2054484T3 (es) Composiciones farmaceuticas que contienen complejos de antigeno-anticuerpo, asi como la utilizacion de las mismas.
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
DE3875306D1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
DE3786173T2 (de) Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten.
ATE108664T1 (de) Verfahren zur verhütung von gvhd.
GR75239B (de)
BE895861A (fr) Agent therapeutique pour le traitement de troubles allergiques, de maladies a complexes immunitaires et de tumeurs
ATE75410T1 (de) Verfahren und vorrichtung zur behandlung von krankheiten.
ES8300477A1 (es) Procedimiento para la preparacion de una composicion para el tratamiento del cancer
PT75226B (en) Method for diagnosing and for the therapeutic treatment of tu- mors diseases
ATE99174T1 (de) Verfahren zur behandlung von gefaesskrankheiten.
IL66086A0 (en) Method and apparatus for the treatment of autoimmune diseases and allergy
CS729987A1 (en) Murine lymphocyte hybridoma fe 6 that produces antibody against human fibrin's fragments and method of its preparation
ATE101054T1 (de) Einrichtung zur diagnostik und behandlung von nasenerkrankungen.

Legal Events

Date Code Title Description
8332 No legal effect for de